HLA-G and neoplasm: Another clinical trial is currently evaluating the safety, tolerability, pharmacokinetics, immune response, and preliminary anti-tumor activity of the RO7515629 drug in participants with advanced or metastatic solid HLA-G+ tumors (NCT05769959).